Kerry is a translation scientist working in the field of immuno-oncology. He holds a lectureship at the University of Oxford and specialises in the delivery of therapeutic viruses, genes and proteins into the tumour microenvironment. His scientific experience ranges from new product innovation all the way through early phase clinical trials to commercial development. In his career to date, Kerry has authored over 60 peer reviewed publications and filed over a dozen patent application. He is also a scientific founder of PsiOxus Therapeutics and the Native Antigen company.